Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Conditions
Brief summary
This laboratory study is looking at DNA in tumor tissue samples from young patients with acute lymphoblastic leukemia. DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment
Detailed description
PRIMARY OBJECTIVE: I. To validate significant associations between SNPs and treatment outcome and toxicity on Children's Cancer Group (CCG)-1891 on an independent sample set from a successor CCG study for standard risk acute lymphoblastic leukemia (ALL), CCG-1952. II. To evaluate the role of SNPs in drug metabolizing enzymes and the development of veno-occlusive disease in patients on CCG-1952. III. To evaluate interactions among genotypes and other risk factors for treatment response in a combined data set of CCG-1891 and CCG-1952 with recently developed analytic tools for high dimensional data. IV. To develop predictive models utilizing genetic information obtained in Aim 1.1 and clinical data to predict treatment response and toxicity. OUTLINE: Tumor tissue samples undergo genotype assessment on the Pyrosequencing platform. Contingency tables and X\^2 test performs a univariate analysis of the risk of relapse and genotype, and multivariable analyses using logistic regression. Cox proportional hazards evaluate the risk of relapse given genotype and other confounders. Genotype patterning, classification and regression trees, and multifactor dimensionality reduction evaluates for patterns of single nucleotide polymorphisms associated with toxicity and relapse risk.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Enrolled in clinical trial CCG-1891 or CCG-1952 with pediatric ALL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Leukemia Relapse | Day 7 | Contingency tables will be used to tabulate the relationship between relapse and genotype, race, leukemia cytogenetics, day 7 bone marrow status, and treatment arm |
| Development of veno-occlusive disease in patients on CCG-1952 | Day 28 | Classification and Regression Trees (CART), genotype patterning, Multifactor Dimensionality Reduction (MDR) techniques will be used to identify SNP combinations associated with risk of relapse and VOD |
| Development of a predictive model of leukemia relapse | Day 28 | Predictive models will be developed utilizing genetic information obtained in Aim 1.1 and clinical data to predict treatment response |
| Development of a predictive model of leukemia toxicity | Day 28 | Predictive models will be developed utilizing genetic information obtained in Aim 1.1 and clinical data to predict treatment toxicity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Development of grade III/IV toxicity as defined by the CCG toxicity criteria | Day 28 | Contingency tables will be used to tabulate categorical toxicities and toxicity severity grade. |
Countries
United States
Outcome results
None listed